This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Myasthenia versus myasthenic.
The question of the limits of the clinical diagnosis of myasthenia gravis is in part one of definitions superimposed on the evolution in our understanding of normal and abnormal neuromuscular junction anatomy, physiology, and pharmacology, complemented by new knowledge of the immunopathogenic events that take place at the neuromuscular junction in the most common form of myasthenia gravis, acquired autoimmune myasthenia gravis. [1,2] In the past, myasthenia gravis was used to describe a series of disorders, most of them quite uncommon or rare, in which there appeared to be a defect in neuromuscular function based on abnormal neurophysiology and on pharmacologic responses to agents that enhanced or inhibited neuromuscular transmission, acting either presynaptically or postsynaptically. In 1982, we still classified myasthenia gravis as generalized vs. ocular, but in the generalized category we included congenital myasthenia gravis. It was recognized that congenital myasthenia gravis comprised several different disorders that did not appear to be immunologically mediated but that did appear to involve the neuromuscular junction based on the clinical picture, neurophysiology, and/or response to cholinesterase inhibitory drugs. [3]
Through the work of several investigators, principally Dr. Andrew Engel and his collaborators (reviewed by Dr. Engel in this supplement and elsewhere [4]), we now understand that congenital myasthenia includes several disorders involving different presynaptic and postsynaptic defects. Some of these have very different neurophysiologic findings from those of classic autoimmune myasthenia gravis, even using traditional clinical neurophysiologic testing. It is of interest that we classified the Lambert-Eaton myasthenic syndrome (LEMS) as a clearly different myasthenic syndrome, although some of the congenital forms of myasthenia are just as clearly presynaptic as LEMS, albeit not immunologically mediated, which we now know is true of LEMS. Should we now reserve the term myasthenia gravis for the acquired, immunologically mediated postsynaptic disorder, be it generalized or …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
